NO326404B1 - Mikroemulsjoner, fremgangsmate for fremstilling derav, samt slike mikroemulsjoner for bruk som et medikament - Google Patents
Mikroemulsjoner, fremgangsmate for fremstilling derav, samt slike mikroemulsjoner for bruk som et medikament Download PDFInfo
- Publication number
- NO326404B1 NO326404B1 NO19981021A NO981021A NO326404B1 NO 326404 B1 NO326404 B1 NO 326404B1 NO 19981021 A NO19981021 A NO 19981021A NO 981021 A NO981021 A NO 981021A NO 326404 B1 NO326404 B1 NO 326404B1
- Authority
- NO
- Norway
- Prior art keywords
- microemulsion
- microemulsion according
- surfactant
- polar phase
- carbon atoms
- Prior art date
Links
- 239000004530 micro-emulsion Substances 0.000 title claims abstract description 76
- 239000003814 drug Substances 0.000 title claims description 12
- 238000000034 method Methods 0.000 title claims description 8
- 238000002360 preparation method Methods 0.000 title description 3
- 239000004094 surface-active agent Substances 0.000 claims abstract description 37
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 31
- 239000000203 mixture Substances 0.000 claims abstract description 29
- 150000001875 compounds Chemical class 0.000 claims abstract description 21
- 239000003981 vehicle Substances 0.000 claims abstract description 15
- 239000003607 modifier Substances 0.000 claims abstract description 14
- 230000002209 hydrophobic effect Effects 0.000 claims abstract description 9
- 231100000252 nontoxic Toxicity 0.000 claims abstract description 6
- 230000003000 nontoxic effect Effects 0.000 claims abstract description 6
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims abstract description 5
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 5
- 239000000787 lecithin Substances 0.000 claims abstract description 5
- 229940067606 lecithin Drugs 0.000 claims abstract description 5
- 235000010445 lecithin Nutrition 0.000 claims abstract description 5
- 150000003408 sphingolipids Chemical class 0.000 claims abstract description 4
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 33
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 21
- 125000004432 carbon atom Chemical group C* 0.000 claims description 18
- 150000004665 fatty acids Chemical class 0.000 claims description 18
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 15
- 239000000194 fatty acid Substances 0.000 claims description 15
- 229930195729 fatty acid Natural products 0.000 claims description 15
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 11
- 239000003921 oil Substances 0.000 claims description 11
- -1 hydroxyethyl lactamide Chemical compound 0.000 claims description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 8
- 150000005690 diesters Chemical class 0.000 claims description 8
- 239000011780 sodium chloride Substances 0.000 claims description 8
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims description 8
- 239000002202 Polyethylene glycol Substances 0.000 claims description 7
- 229920001223 polyethylene glycol Polymers 0.000 claims description 7
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 6
- 239000000600 sorbitol Substances 0.000 claims description 6
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 claims description 5
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 5
- 239000003833 bile salt Substances 0.000 claims description 5
- 229940093761 bile salts Drugs 0.000 claims description 5
- 238000007911 parenteral administration Methods 0.000 claims description 5
- 229940068918 polyethylene glycol 400 Drugs 0.000 claims description 5
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 4
- 229930195725 Mannitol Natural products 0.000 claims description 4
- 239000004698 Polyethylene Substances 0.000 claims description 4
- 150000002016 disaccharides Chemical class 0.000 claims description 4
- 239000000594 mannitol Substances 0.000 claims description 4
- 235000010355 mannitol Nutrition 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 150000002772 monosaccharides Chemical class 0.000 claims description 4
- 229940113115 polyethylene glycol 200 Drugs 0.000 claims description 4
- 229940068886 polyethylene glycol 300 Drugs 0.000 claims description 4
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 claims description 3
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 claims description 3
- 239000004359 castor oil Substances 0.000 claims description 3
- 235000019438 castor oil Nutrition 0.000 claims description 3
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims description 3
- 238000010438 heat treatment Methods 0.000 claims description 3
- 229940083466 soybean lecithin Drugs 0.000 claims description 3
- 150000005691 triesters Chemical class 0.000 claims description 3
- RSBHKNDSJJBCMN-UHFFFAOYSA-N 1-(1-hydroxyethyl)pyrrolidin-2-one Chemical compound CC(O)N1CCCC1=O RSBHKNDSJJBCMN-UHFFFAOYSA-N 0.000 claims description 2
- 229940114069 12-hydroxystearate Drugs 0.000 claims description 2
- KIHBGTRZFAVZRV-UHFFFAOYSA-N 2-hydroxyoctadecanoic acid Chemical class CCCCCCCCCCCCCCCCC(O)C(O)=O KIHBGTRZFAVZRV-UHFFFAOYSA-N 0.000 claims description 2
- 229940127291 Calcium channel antagonist Drugs 0.000 claims description 2
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 claims description 2
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 claims description 2
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 claims description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 2
- 229930006000 Sucrose Natural products 0.000 claims description 2
- 239000003741 agents affecting lipid metabolism Substances 0.000 claims description 2
- 230000001476 alcoholic effect Effects 0.000 claims description 2
- 229930013930 alkaloid Natural products 0.000 claims description 2
- 150000003797 alkaloid derivatives Chemical class 0.000 claims description 2
- 125000000217 alkyl group Chemical group 0.000 claims description 2
- 230000003444 anaesthetic effect Effects 0.000 claims description 2
- 230000001430 anti-depressive effect Effects 0.000 claims description 2
- 239000003146 anticoagulant agent Substances 0.000 claims description 2
- 229940127219 anticoagulant drug Drugs 0.000 claims description 2
- 239000000935 antidepressant agent Substances 0.000 claims description 2
- 239000003963 antioxidant agent Substances 0.000 claims description 2
- 230000003078 antioxidant effect Effects 0.000 claims description 2
- 230000003115 biocidal effect Effects 0.000 claims description 2
- 239000000480 calcium channel blocker Substances 0.000 claims description 2
- 239000000824 cytostatic agent Substances 0.000 claims description 2
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 claims description 2
- 229940093471 ethyl oleate Drugs 0.000 claims description 2
- 150000002194 fatty esters Chemical class 0.000 claims description 2
- 229930182478 glucoside Natural products 0.000 claims description 2
- 229960003444 immunosuppressant agent Drugs 0.000 claims description 2
- 230000001861 immunosuppressant effect Effects 0.000 claims description 2
- 239000003018 immunosuppressive agent Substances 0.000 claims description 2
- XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 claims description 2
- 239000003176 neuroleptic agent Substances 0.000 claims description 2
- 230000000701 neuroleptic effect Effects 0.000 claims description 2
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims description 2
- 229940126409 proton pump inhibitor Drugs 0.000 claims description 2
- 239000000612 proton pump inhibitor Substances 0.000 claims description 2
- 239000002461 renin inhibitor Substances 0.000 claims description 2
- 229940086526 renin-inhibitors Drugs 0.000 claims description 2
- 150000003431 steroids Chemical class 0.000 claims description 2
- 238000003756 stirring Methods 0.000 claims description 2
- 239000005720 sucrose Substances 0.000 claims description 2
- 239000002260 anti-inflammatory agent Substances 0.000 claims 1
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 1
- 229940005513 antidepressants Drugs 0.000 claims 1
- 239000002876 beta blocker Substances 0.000 claims 1
- 229940097320 beta blocking agent Drugs 0.000 claims 1
- 229920000573 polyethylene Polymers 0.000 claims 1
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 14
- 239000012071 phase Substances 0.000 description 14
- 230000004872 arterial blood pressure Effects 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 10
- 241001465754 Metazoa Species 0.000 description 9
- 241000700159 Rattus Species 0.000 description 9
- 238000005191 phase separation Methods 0.000 description 7
- 238000001802 infusion Methods 0.000 description 5
- 235000019198 oils Nutrition 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 239000011521 glass Substances 0.000 description 4
- 150000002632 lipids Chemical class 0.000 description 4
- RZTAMFZIAATZDJ-HNNXBMFYSA-N 5-o-ethyl 3-o-methyl (4s)-4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)[C@@H]1C1=CC=CC(Cl)=C1Cl RZTAMFZIAATZDJ-HNNXBMFYSA-N 0.000 description 3
- 229920000604 Polyethylene Glycol 200 Polymers 0.000 description 3
- 229920002556 Polyethylene Glycol 300 Polymers 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 210000001367 artery Anatomy 0.000 description 3
- 229960003580 felodipine Drugs 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 239000007791 liquid phase Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- AZUYLZMQTIKGSC-UHFFFAOYSA-N 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one Chemical compound ClC=1C(=C2C=NNC2=CC=1C)C=1C(=NN(C=1C)C1CC2(CN(C2)C(C=C)=O)C1)C=1C=C2C=NN(C2=CC=1)C AZUYLZMQTIKGSC-UHFFFAOYSA-N 0.000 description 2
- 244000025254 Cannabis sativa Species 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 239000008139 complexing agent Substances 0.000 description 2
- 239000003792 electrolyte Substances 0.000 description 2
- 230000000004 hemodynamic effect Effects 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000005063 solubilization Methods 0.000 description 2
- 230000007928 solubilization Effects 0.000 description 2
- 230000003381 solubilizing effect Effects 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- VBCKYDVWOPZOBA-UHFFFAOYSA-N 2-(oxolan-2-ylmethoxymethyl)oxolane Chemical compound C1CCOC1COCC1CCCO1 VBCKYDVWOPZOBA-UHFFFAOYSA-N 0.000 description 1
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- NZXKDOXHBHYTKP-UHFFFAOYSA-N Metohexital Chemical compound CCC#CC(C)C1(CC=C)C(=O)NC(=O)N(C)C1=O NZXKDOXHBHYTKP-UHFFFAOYSA-N 0.000 description 1
- 241000219000 Populus Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 210000000702 aorta abdominal Anatomy 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000000059 bradycardiac effect Effects 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- 230000001085 cytostatic effect Effects 0.000 description 1
- OGQYPPBGSLZBEG-UHFFFAOYSA-N dimethyl(dioctadecyl)azanium Chemical compound CCCCCCCCCCCCCCCCCC[N+](C)(C)CCCCCCCCCCCCCCCCCC OGQYPPBGSLZBEG-UHFFFAOYSA-N 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000008344 egg yolk phospholipid Substances 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 230000002584 immunomodulator Effects 0.000 description 1
- RXXXUIOZOITBII-UHFFFAOYSA-N indeno[1,2-g]indole Chemical compound C1=C2C=CC=CC2=C2C1=C1N=CC=C1C=C2 RXXXUIOZOITBII-UHFFFAOYSA-N 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 239000002563 ionic surfactant Substances 0.000 description 1
- 229940074928 isopropyl myristate Drugs 0.000 description 1
- 229940075495 isopropyl palmitate Drugs 0.000 description 1
- 210000004731 jugular vein Anatomy 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 210000004705 lumbosacral region Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000010907 mechanical stirring Methods 0.000 description 1
- 229960001620 methohexital sodium Drugs 0.000 description 1
- KDXZREBVGAGZHS-UHFFFAOYSA-M methohexital sodium Chemical compound [Na+].CCC#CC(C)C1(CC=C)C(=O)N=C([O-])N(C)C1=O KDXZREBVGAGZHS-UHFFFAOYSA-M 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 239000007764 o/w emulsion Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 229920000223 polyglycerol Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 210000002254 renal artery Anatomy 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000005549 size reduction Methods 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000013222 sprague-dawley male rat Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000037317 transdermal delivery Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Dispersion Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Colloid Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE9503143A SE9503143D0 (sv) | 1995-09-12 | 1995-09-12 | New preparation |
| PCT/SE1996/001097 WO1997009964A1 (en) | 1995-09-12 | 1996-09-04 | Microemulsions for use as vehicles for administration of active compounds |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO981021D0 NO981021D0 (no) | 1998-03-09 |
| NO981021L NO981021L (no) | 1998-03-09 |
| NO326404B1 true NO326404B1 (no) | 2008-11-24 |
Family
ID=20399446
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO19981021A NO326404B1 (no) | 1995-09-12 | 1998-03-09 | Mikroemulsjoner, fremgangsmate for fremstilling derav, samt slike mikroemulsjoner for bruk som et medikament |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US6602511B2 (xx) |
| EP (1) | EP0850046B1 (xx) |
| JP (1) | JP4203123B2 (xx) |
| KR (1) | KR100448953B1 (xx) |
| CN (1) | CN1160057C (xx) |
| AT (1) | ATE228822T1 (xx) |
| AU (1) | AU702366B2 (xx) |
| BR (1) | BR9610089A (xx) |
| CA (1) | CA2230730C (xx) |
| CZ (1) | CZ64398A3 (xx) |
| DE (1) | DE69625213T2 (xx) |
| DK (1) | DK0850046T3 (xx) |
| EE (1) | EE9800070A (xx) |
| ES (1) | ES2186802T3 (xx) |
| HU (1) | HUP9901215A3 (xx) |
| IL (1) | IL123638A (xx) |
| IS (1) | IS4675A (xx) |
| MX (1) | MX9801755A (xx) |
| NO (1) | NO326404B1 (xx) |
| NZ (1) | NZ318530A (xx) |
| PL (1) | PL325825A1 (xx) |
| PT (1) | PT850046E (xx) |
| RU (1) | RU2164134C2 (xx) |
| SE (1) | SE9503143D0 (xx) |
| SK (1) | SK282390B6 (xx) |
| TR (1) | TR199800437T1 (xx) |
| WO (1) | WO1997009964A1 (xx) |
Families Citing this family (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9503143D0 (sv) | 1995-09-12 | 1995-09-12 | Astra Ab | New preparation |
| US5840737A (en) | 1996-01-04 | 1998-11-24 | The Curators Of The University Of Missouri | Omeprazole solution and method for using same |
| US6489346B1 (en) | 1996-01-04 | 2002-12-03 | The Curators Of The University Of Missouri | Substituted benzimidazole dosage forms and method of using same |
| US6458373B1 (en) | 1997-01-07 | 2002-10-01 | Sonus Pharmaceuticals, Inc. | Emulsion vehicle for poorly soluble drugs |
| US7030155B2 (en) | 1998-06-05 | 2006-04-18 | Sonus Pharmaceuticals, Inc. | Emulsion vehicle for poorly soluble drugs |
| CA2339991C (en) * | 1998-08-13 | 2007-01-02 | Cima Labs Inc. | Microemulsions as solid dosage forms for oral administration |
| DE19859427A1 (de) * | 1998-12-22 | 2000-06-29 | Beiersdorf Ag | Kosmetische oder pharmazeutische lecithinhaltige Gele oder niedrigviskose, lecithinhaltige O/W-Mikroemulsionen |
| GB9912476D0 (en) | 1999-05-28 | 1999-07-28 | Novartis Ag | Organic compounds |
| FR2795960B1 (fr) * | 1999-07-05 | 2001-10-19 | Sanofi Elf | Microemulsions stables pour l'administration d'acides gras a l'homme ou a l'animal, et utilisation de ces microemulsions |
| KR100441167B1 (ko) * | 2001-12-27 | 2004-07-21 | 씨제이 주식회사 | 마이크로에멀젼 예비 농축액 조성물 |
| US7380606B2 (en) * | 2002-03-01 | 2008-06-03 | Cesi Chemical, A Flotek Company | Composition and process for well cleaning |
| US7811594B2 (en) | 2002-03-28 | 2010-10-12 | Beiersdorf Ag | Crosslinked oil droplet-based cosmetic or pharmaceutical emulsions |
| DE10213957A1 (de) * | 2002-03-28 | 2003-10-09 | Beiersdorf Ag | Vernetzte kosmetische oder pharmazeutische phospholipidhaltige Gele und Emulsionen auf der Basis von ethylenoxidhaltigen oder propylenoxidhaltigen Emulgatoren |
| DE10213955A1 (de) * | 2002-03-28 | 2003-10-09 | Beiersdorf Ag | Kosmetische oder pharmazeutische phospholipidhaltige, niedrigviskose (versprühbare) O/W-Emulsionen |
| US20050124705A1 (en) * | 2002-03-28 | 2005-06-09 | Beiersdorf Ag | Cosmetic or pharmaceutical, low-viscosity oil-in-water emulsions containing phospholipids |
| ATE344026T1 (de) * | 2002-06-28 | 2006-11-15 | Speedel Pharma Ag | Pharmazeutische formulierung mit einem nichtpeptidischen renin-hemmer und surfactant |
| DE60304102T3 (de) * | 2002-12-27 | 2013-12-24 | Kao Corp. | Hautreinigungszusammensetzung |
| US8993599B2 (en) | 2003-07-18 | 2015-03-31 | Santarus, Inc. | Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them |
| PE20050596A1 (es) * | 2003-12-19 | 2005-10-18 | Novartis Ag | Microemulsion que comprende un inhibidor renina |
| CA2556185C (en) * | 2004-02-13 | 2010-09-21 | Bioavailability, Inc. | A microemulsion preparation of high concentration propofol for anesthetic uses |
| US7727576B2 (en) * | 2004-04-16 | 2010-06-01 | Hewlett-Packard Development Company, L.P. | System and a method for producing layered oral dosage forms |
| US20050232974A1 (en) * | 2004-04-19 | 2005-10-20 | Gore Makarand P | System and a method for pharmaceutical dosage preparation using jettable microemulsions |
| US8906940B2 (en) | 2004-05-25 | 2014-12-09 | Santarus, Inc. | Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them |
| US20060222692A1 (en) * | 2005-03-31 | 2006-10-05 | Fairfield Clinical Trials Llc | Method and compositions for transdermal administration of antimicrobial medications |
| US11311477B2 (en) * | 2006-03-07 | 2022-04-26 | Sgn Nanopharma Inc. | Ophthalmic preparations |
| US10137083B2 (en) * | 2006-03-07 | 2018-11-27 | SGN Nanopharma Inc | Ophthalmic preparations |
| US9918934B2 (en) * | 2006-12-12 | 2018-03-20 | Edgar Joel Acosta-Zara | Linker-based lecithin microemulsion delivery vehicles |
| EP1938801A1 (en) * | 2006-12-22 | 2008-07-02 | Biofrontera Bioscience GmbH | Nanoemulsion |
| US20080199589A1 (en) * | 2007-02-20 | 2008-08-21 | Cargill, Incorporated | Lipid Microemulsions |
| EP1985298A1 (en) | 2007-04-24 | 2008-10-29 | Azad Pharma AG | Ophtalmic oil-in-water emulsions containing prostaglandins |
| US9222013B1 (en) | 2008-11-13 | 2015-12-29 | Cesi Chemical, Inc. | Water-in-oil microemulsions for oilfield applications |
| MX336071B (es) | 2009-08-14 | 2016-01-06 | Opko Health Inc | Formulaciones intravenosas de antagonistas de neurocinina 1. |
| JP4834775B2 (ja) | 2010-03-04 | 2011-12-14 | 株式会社 資生堂 | 日焼け止め用組成物 |
| NL2005365C2 (en) * | 2010-09-17 | 2012-03-20 | Univ Delft Tech | Carbon nanostructures and networks produced by chemical vapor deposition. |
| EP2838970B1 (en) | 2012-04-15 | 2016-12-28 | Flotek Chemistry, LLC | Surfactant formulations for foam flooding |
| US11407930B2 (en) | 2012-05-08 | 2022-08-09 | Flotek Chemistry, Llc | Compositions and methods for enhancement of production of liquid and gaseous hydrocarbons |
| US9200192B2 (en) | 2012-05-08 | 2015-12-01 | Cesi Chemical, Inc. | Compositions and methods for enhancement of production of liquid and gaseous hydrocarbons |
| KR20150023876A (ko) * | 2012-06-28 | 2015-03-05 | 맥네일-피피씨, 인코포레이티드 | 라세카도트릴 지질 조성물 |
| US9801819B2 (en) * | 2012-06-28 | 2017-10-31 | Johnson & Johnson Consumer Inc. | Racecadotril compositions |
| US10000693B2 (en) | 2013-03-14 | 2018-06-19 | Flotek Chemistry, Llc | Methods and compositions for use in oil and/or gas wells |
| US10590332B2 (en) | 2013-03-14 | 2020-03-17 | Flotek Chemistry, Llc | Siloxane surfactant additives for oil and gas applications |
| US9464223B2 (en) | 2013-03-14 | 2016-10-11 | Flotek Chemistry, Llc | Methods and compositions for use in oil and/or gas wells |
| US9428683B2 (en) | 2013-03-14 | 2016-08-30 | Flotek Chemistry, Llc | Methods and compositions for stimulating the production of hydrocarbons from subterranean formations |
| US10717919B2 (en) | 2013-03-14 | 2020-07-21 | Flotek Chemistry, Llc | Methods and compositions for use in oil and/or gas wells |
| US9884988B2 (en) | 2013-03-14 | 2018-02-06 | Flotek Chemistry, Llc | Methods and compositions for use in oil and/or gas wells |
| US11254856B2 (en) | 2013-03-14 | 2022-02-22 | Flotek Chemistry, Llc | Methods and compositions for use in oil and/or gas wells |
| US10053619B2 (en) | 2013-03-14 | 2018-08-21 | Flotek Chemistry, Llc | Siloxane surfactant additives for oil and gas applications |
| US11180690B2 (en) | 2013-03-14 | 2021-11-23 | Flotek Chemistry, Llc | Diluted microemulsions with low surface tensions |
| US10577531B2 (en) | 2013-03-14 | 2020-03-03 | Flotek Chemistry, Llc | Polymers and emulsions for use in oil and/or gas wells |
| US10941106B2 (en) | 2013-03-14 | 2021-03-09 | Flotek Chemistry, Llc | Methods and compositions incorporating alkyl polyglycoside surfactant for use in oil and/or gas wells |
| US9868893B2 (en) | 2013-03-14 | 2018-01-16 | Flotek Chemistry, Llc | Methods and compositions for use in oil and/or gas wells |
| US10421707B2 (en) | 2013-03-14 | 2019-09-24 | Flotek Chemistry, Llc | Methods and compositions incorporating alkyl polyglycoside surfactant for use in oil and/or gas wells |
| US9321955B2 (en) | 2013-06-14 | 2016-04-26 | Flotek Chemistry, Llc | Methods and compositions for stimulating the production of hydrocarbons from subterranean formations |
| US9068108B2 (en) | 2013-03-14 | 2015-06-30 | Cesi Chemical, Inc. | Methods and compositions for stimulating the production of hydrocarbons from subterranean formations |
| US10287483B2 (en) | 2013-03-14 | 2019-05-14 | Flotek Chemistry, Llc | Methods and compositions for use in oil and/or gas wells comprising a terpene alcohol |
| US9890624B2 (en) | 2014-02-28 | 2018-02-13 | Eclipse Ior Services, Llc | Systems and methods for the treatment of oil and/or gas wells with a polymeric material |
| US9890625B2 (en) | 2014-02-28 | 2018-02-13 | Eclipse Ior Services, Llc | Systems and methods for the treatment of oil and/or gas wells with an obstruction material |
| US9505970B2 (en) | 2014-05-14 | 2016-11-29 | Flotek Chemistry, Llc | Methods and compositions for use in oil and/or gas wells |
| US10294757B2 (en) | 2014-07-28 | 2019-05-21 | Flotek Chemistry, Llc | Methods and compositions related to gelled layers in oil and/or gas wells |
| JP2017181387A (ja) * | 2016-03-31 | 2017-10-05 | 株式会社ポーラファルマ | 医薬組成物の形成する膜の評価方法 |
| US10934472B2 (en) | 2017-08-18 | 2021-03-02 | Flotek Chemistry, Llc | Compositions comprising non-halogenated solvents for use in oil and/or gas wells and related methods |
| US11053433B2 (en) | 2017-12-01 | 2021-07-06 | Flotek Chemistry, Llc | Methods and compositions for stimulating the production of hydrocarbons from subterranean formations |
| CN109401745B (zh) * | 2018-11-21 | 2021-03-12 | 西南石油大学 | 一种自适应流度控制体系及其在高温高盐油藏的应用 |
| US11104843B2 (en) | 2019-10-10 | 2021-08-31 | Flotek Chemistry, Llc | Well treatment compositions and methods comprising certain microemulsions and certain clay control additives exhibiting synergistic effect of enhancing clay swelling protection and persistency |
| US11512243B2 (en) | 2020-10-23 | 2022-11-29 | Flotek Chemistry, Llc | Microemulsions comprising an alkyl propoxylated sulfate surfactant, and related methods |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2553666B1 (fr) | 1983-10-21 | 1986-10-31 | Correia Gabriel | Dispositif permettant de sentir individuellement odeurs et parfums en liaison avec des images et des sons |
| DE3406497A1 (de) | 1984-02-23 | 1985-09-05 | Mueller Bernhard Willi Werner | Hochdisperse pharmazeutische mehrkomponentensysteme und verfahren zu ihrer herstellung |
| IL78929A0 (en) | 1985-07-29 | 1986-09-30 | Abbott Lab | Microemulsion compositions for parenteral administration |
| FR2628632B1 (fr) * | 1988-03-18 | 1992-04-03 | Gattefosse Ets Sa | Microemulsions a usage cosmetique ou pharmaceutique |
| AU614465B2 (en) | 1989-04-05 | 1991-08-29 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Medicinal emulsions |
| US5364632A (en) * | 1989-04-05 | 1994-11-15 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Medicinal emulsions |
| WO1992018147A1 (en) | 1991-04-19 | 1992-10-29 | Affinity Biotech, Inc. | Convertible microemulsion formulations |
| IL102633A0 (en) | 1991-07-26 | 1993-01-14 | Smithkline Beecham Corp | Compositions |
| FR2709666B1 (fr) | 1993-09-07 | 1995-10-13 | Oreal | Composition cosmétique ou dermatologique constituée d'une émulsion huile dans eau à base de globules huileux pourvus d'un enrobage cristal liquide lamellaire. |
| DE4338046A1 (de) | 1993-11-08 | 1995-05-11 | Dietl Hans | Fettlösliche Arzneimittel erhaltende flüssige pharmazeutische Zubereitung zur oralen Anwendung |
| FR2730932B1 (fr) | 1995-02-27 | 1997-04-04 | Oreal | Nanoemulsion transparente a base de lipides amphiphiles non-ioniques fluides et utilisation en cosmetique ou en dermopharmacie |
| SE9503143D0 (sv) | 1995-09-12 | 1995-09-12 | Astra Ab | New preparation |
-
1995
- 1995-09-12 SE SE9503143A patent/SE9503143D0/xx unknown
-
1996
- 1996-09-04 NZ NZ318530A patent/NZ318530A/en not_active IP Right Cessation
- 1996-09-04 CN CNB961981377A patent/CN1160057C/zh not_active Expired - Fee Related
- 1996-09-04 PT PT96931319T patent/PT850046E/pt unknown
- 1996-09-04 TR TR1998/00437T patent/TR199800437T1/xx unknown
- 1996-09-04 AT AT96931319T patent/ATE228822T1/de active
- 1996-09-04 DK DK96931319T patent/DK0850046T3/da active
- 1996-09-04 BR BR9610089A patent/BR9610089A/pt not_active IP Right Cessation
- 1996-09-04 PL PL96325825A patent/PL325825A1/xx unknown
- 1996-09-04 SK SK283-98A patent/SK282390B6/sk unknown
- 1996-09-04 EE EE9800070A patent/EE9800070A/xx unknown
- 1996-09-04 ES ES96931319T patent/ES2186802T3/es not_active Expired - Lifetime
- 1996-09-04 HU HU9901215A patent/HUP9901215A3/hu unknown
- 1996-09-04 JP JP51187897A patent/JP4203123B2/ja not_active Expired - Fee Related
- 1996-09-04 AU AU70037/96A patent/AU702366B2/en not_active Ceased
- 1996-09-04 RU RU98106482/14A patent/RU2164134C2/ru active
- 1996-09-04 CZ CZ98643A patent/CZ64398A3/cs unknown
- 1996-09-04 WO PCT/SE1996/001097 patent/WO1997009964A1/en active IP Right Grant
- 1996-09-04 IL IL12363896A patent/IL123638A/en not_active IP Right Cessation
- 1996-09-04 DE DE69625213T patent/DE69625213T2/de not_active Expired - Lifetime
- 1996-09-04 EP EP96931319A patent/EP0850046B1/en not_active Expired - Lifetime
- 1996-09-04 US US08/718,485 patent/US6602511B2/en not_active Expired - Fee Related
- 1996-09-04 CA CA002230730A patent/CA2230730C/en not_active Expired - Fee Related
- 1996-09-04 KR KR10-1998-0701818A patent/KR100448953B1/ko not_active IP Right Cessation
-
1998
- 1998-02-25 IS IS4675A patent/IS4675A/is unknown
- 1998-03-05 MX MX9801755A patent/MX9801755A/es not_active IP Right Cessation
- 1998-03-09 NO NO19981021A patent/NO326404B1/no not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO326404B1 (no) | Mikroemulsjoner, fremgangsmate for fremstilling derav, samt slike mikroemulsjoner for bruk som et medikament | |
| KR100410937B1 (ko) | 프로포폴을 함유하는 혈관주사용 마취제 조성물 | |
| KR100345627B1 (ko) | 단기간작용하는디히드로피리딘을함유하는약제학적유제및그의제조방법 | |
| CN100479856C (zh) | 用于亲水性化合物非肠道给药的缓释药物组合物 | |
| RU2028142C1 (ru) | Фармацевтический раствор | |
| EP0650721B1 (en) | Cyclosporin soft capsule | |
| KR101391020B1 (ko) | 수난용성 약제를 함유한 약학 조성물 | |
| WO2004041249A1 (en) | Microemulsion concentrate for oral administration of water-insoluble anti-cold drug and method for preparing same | |
| DK175504B1 (da) | Farmaceutisk præparat indeholdende 3alfa-hydroxy-5beta-pregnan-20-on og fremstilling deraf | |
| EA033935B1 (ru) | Инъекционный состав бупренорфина | |
| AU574438B2 (en) | Method for directed visceral metabolism of medium chain triglycerides | |
| JP3132085B2 (ja) | 脂肪乳剤 | |
| JP2632010B2 (ja) | シクロスポリン製剤 | |
| TWI819756B (zh) | 包含塞納布啡的藥物組合物 | |
| JPH05229941A (ja) | フェノール誘導体を含有する注射用乳剤 | |
| JP2002540158A (ja) | レトロウイルスプロテアーゼインヒビター用医薬エマルジョン | |
| JPH0532549A (ja) | 脂肪乳剤 | |
| WO2002009670A1 (en) | Liquid or semi-solid pharmaceutical excipient and pharmaceutical composition comprising the same | |
| JPS6023311A (ja) | 難溶性物質の水溶液 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM1K | Lapsed by not paying the annual fees |